Allergy Therapeutics (AGY) AI Stock Analysis

• Market Cap: £381.32M
• Dividend Yield: N/A
• Average Volume (3M): 353.95K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: 4.50%
• EPS Growth: 74.32%
• Country: UK
• Employees: 612
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 4,766,440,000
• 10 Day Avg. Volume: 584,158
• 30 Day Avg. Volume: 353,955
• PEG Ratio: >-0.01
• Price to Book (P/B): 3.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: 8.00p ▲(0.00%Upside)

Allergy Therapeutics has significant financial challenges, which are the most impactful factor on its stock score. However, technical analysis shows some positive momentum, and promising corporate events suggest potential future growth, partially offsetting financial weaknesses. Valuation concerns remain due to negative earnings.

Allergy Therapeutics Business Overview & Revenue Model

Company Description

Allergy Therapeutics (AGY) is a leading biotechnology company specializing in the development and commercialization of allergy immunotherapy solutions. Operating within the healthcare and pharmaceuticals sector, the company focuses on transforming the treatment of allergies through innovative vaccines and treatments. Its core products are designed to provide long-term relief to patients suffering from various allergic conditions, significantly improving their quality of life.

How the Company Makes Money

Allergy Therapeutics generates revenue primarily through the sale of its allergy immunotherapy products. The company's key revenue streams include direct sales of its proprietary allergy vaccines to healthcare providers, clinics, and hospitals. Additionally, the company may engage in partnerships and licensing agreements with other pharmaceutical companies to expand the reach and distribution of its products. Significant factors contributing to its earnings include ongoing research and development activities aimed at enhancing product efficacy and the expansion of its product portfolio to address a broader range of allergic conditions.

Allergy Therapeutics Financial Statement Overview

Summary

Allergy Therapeutics is experiencing financial difficulties, with declining revenues and consistent net losses impacting profitability metrics. The balance sheet indicates high leverage and a weakened equity position, while cash flow challenges suggest liquidity pressures. Strategic adjustments are required to improve financial health and stability.

Income Statement

The company has faced declining revenue over the past two years, with a noticeable revenue decrease in the most recent year. Gross profit margin decreased from previous years, and the net profit margin is negative, indicating losses. EBIT and EBITDA margins are also negative, suggesting operational challenges and reduced profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage. Stockholders' equity has drastically decreased, impacting the equity ratio negatively. The return on equity is negative due to consistent net losses, highlighting financial instability.

Cash Flow

Operating cash flow is negative and declining, highlighting cash management issues. The free cash flow remains negative, and the free cash flow to net income ratio is unfavorable. Despite a positive financing cash flow, overall cash flow indicators reflect financial strain.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	55.66M	55.20M	59.59M	72.77M	84.33M	78.20M
Gross Profit	30.08M	29.74M	32.69M	48.95M	61.80M	57.51M
EBITDA	-27.50M	-30.74M	-36.24M	-8.69M	7.61M	11.69M
Net Income	-35.65M	-40.22M	-43.07M	-13.78M	2.89M	7.06M
Balance Sheet
Total Assets	72.97M	64.83M	66.77M	72.95M	88.09M	86.22M
Cash, Cash Equivalents and Short-Term Investments	21.68M	12.91M	14.85M	20.52M	40.27M	36.96M
Total Debt	44.52M	30.99M	35.99M	10.53M	11.17M	12.18M
Total Liabilities	80.12M	61.12M	64.70M	35.18M	39.55M	42.44M
Stockholders Equity	-7.15M	3.71M	2.07M	37.77M	48.53M	43.78M
Cash Flow
Free Cash Flow	-32.54M	-35.54M	-35.59M	-17.17M	5.95M	9.73M
Operating Cash Flow	-29.48M	-32.14M	-30.92M	-14.11M	8.52M	12.28M
Investing Cash Flow	-993.00K	-1.20M	-4.67M	-3.06M	-2.76M	-2.77M
Financing Cash Flow	38.61M	31.43M	29.91M	-2.64M	-2.03M	-110.00K

Allergy Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Positive. The current price of 8 is above the 20-day moving average (MA) of 7.20, above the 50-day MA of 7.05, and above the 200-day MA of 6.24, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 61.53 is Neutral, neither overbought nor oversold. The STOCH value of 86.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AGY.

Allergy Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIK	79 Outperform	£4.37B	15.61	15.79%	2.91%	5.83%	83.35%
Sector *	59 Neutral	£5.95B	9.21	-57.69%	4.67%	15.15%	-8.16%
AGY	53 Neutral	£381.32M	―	-369.20%	―	4.50%	74.32%

Allergy Therapeutics Corporate Events

Allergy Therapeutics Unveils Promising Research at EAACI 2025

Allergy Therapeutics announced key scientific findings at the EAACI 2025 Congress, highlighting advancements in their research portfolio. The company presented promising results from its peanut allergy vaccine candidate and Grass MATA MPL immunotherapy, both showing potential to transform patient care by improving quality of life and inducing beneficial immune responses. These developments underscore the company’s commitment to expanding its VLP platform in food allergies and enhancing treatment options for allergic diseases.

Allergy Therapeutics and EAACI Honor Early Career Researcher

Allergy Therapeutics, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), announced Dr. Janice Layhadi as the winner of the EAACI Early Career Research Award. This award supports young researchers in allergen immunotherapy, providing essential funding to advance their research. Dr. Layhadi’s work focuses on biomarker discovery in allergen immunotherapy, which is expected to enhance understanding and treatment of allergic conditions, ultimately improving patient outcomes.